• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Korean Med Sci . Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young

tetano

Editor, Senior Moderator
J Korean Med Sci


. 2022 Mar 7;37(9):e70.
doi: 10.3346/jkms.2022.37.e70.
Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults


Jihye Um[SUP] #[/SUP][SUP] 1 [/SUP], Youn Young Choi[SUP] #[/SUP][SUP] 1 2 [/SUP], Gayeon Kim[SUP] 3 [/SUP], Min-Kyung Kim[SUP] 3 [/SUP], Kyung-Shin Lee[SUP] 1 [/SUP], Ho Kyung Sung[SUP] 1 [/SUP], Byung Chul Kim[SUP] 4 [/SUP], Yoo-Kyoung Lee[SUP] 4 [/SUP], Hee-Chang Jang[SUP] 4 [/SUP], Ji Hwan Bang[SUP] 5 [/SUP], Ki-Hyun Chung[SUP] 2 [/SUP], Myoung-Don Oh[SUP] 6 [/SUP], Jun-Sun Park[SUP] 7 [/SUP], Jaehyun Jeon[SUP] 1 8 [/SUP]



Affiliations

Abstract

Concerns about the effectiveness of current vaccines against the rapidly spreading severe acute respiratory syndrome-coronavirus-2 omicron (B.1.1.529) variant are increasing. This study aimed to assess neutralizing antibody activity against the wild-type (BetaCoV/Korea/KCDC03/2020), delta, and omicron variants after full primary and booster vaccinations with BNT162b2. A plaque reduction neutralization test was employed to determine 50% neutralizing dilution (ND[SUB]50[/SUB]) titers in serum samples. ND[SUB]50[/SUB] titers against the omicron variant (median [interquartile range], 5.3 [< 5.0-12.7]) after full primary vaccination were lower than those against the wild-type (144.8 [44.7-294.0]) and delta (24.3 [14.3-81.1]) variants. Furthermore, 19/30 participants (63.3%) displayed lower ND[SUB]50[/SUB] titers than the detection threshold (< 10.0) against omicron after full primary vaccination. However, the booster vaccine significantly increased ND[SUB]50[/SUB] titers against BetaCoV/Korea/KCDC03/2020, delta, and omicron, although titers against omicron remained lower than those against the other variants (P < 0.001). Our study suggests that booster vaccination with BNT162b2 significantly increases humoral immunity against the omicron variant.

Keywords: Antibodies; COVID-19 Vaccine; Immunity; Omicron Variant; Republic of Korea.
 
Back
Top Bottom